GHK-Cu: what it is, what it costs, and who sells it

GHK-Cu is the copper(II) complex of a three-amino-acid peptide, glycyl-L-histidyl- L-lysine — a molecule naturally present in human plasma, where it binds copper and is reported to decline in concentration with age. That's a real point of chemical distinction from synthetic fragments like BPC-157 or TB-500, which have no natural counterpart circulating in the body. No FDA-approved GHK-Cu drug product exists in any form: DailyMed lists only topical, over-the-counter cosmetic listings — face and hair serums, a sunscreen — each listing copper tripeptide-1 as one ingredient among several, not an FDA-reviewed drug application.

Compounded, injectable GHK-Cu is a different product entirely — sterile lyophilized powder in a vial, reconstituted with bacteriostatic water, sold for uses no controlled human trial has ever tested. It is what every provider on the board below sells.

A direct PubMed search filtered to clinical trials and RCTs returns exactly three results for GHK-Cu, ever: two human trials — both topical — and one animal trial, also topical. Neither human trial beat its own comparator on its primary endpoint: a 1992 venous-ulcer trial found the GHK-Cu cream performed no better than plain placebo, and a 2006 laser-resurfacing trial found no significant objective difference in erythema resolution or wrinkle improvement, though patient-reported satisfaction was higher. Narrow the question to the injectable, systemic form this board sells, and the record drops from thin to essentially empty: zero published human trials exist, only a handful of animal studies scattered across unrelated disease models. Read the full breakdown, by route, in our full GHK-Cu evidence review.

Injectable GHK-Cu sat in FDA's interim 503A Category 2 (significant safety risk) bulk-substances list from 2023, alongside BPC-157 and TB-500, and was removed on April 15, 2026 via nomination withdrawal — a procedural change, not a safety finding. Unlike BPC-157 and TB-500, both of which have already had their FDA Pharmacy Compounding Advisory Committee hearing and vote, injectable GHK-Cu was not among the seven substances reviewed at FDA's July 23-24, 2026 meeting. FDA has said it will consult its committee on injectable GHK-Cu at a separate meeting before the end of February 2027 — not yet held as of this page's last check, putting it a full procedural step behind its own peptide-market neighbors. See our side-effects review for the full regulatory timeline.

Neither of the two topical human trials reports a clean, distinct safety tally for GHK-Cu specifically — an era-of-reporting limitation, not a clean safety result. For the injectable, systemic form, no human safety data exists at all: not one dedicated toxicology or adverse-event study has been published. The handful of animal studies that do exist report no adverse findings, but none was designed as a safety study, and none tells a reader what's actually in a specific vial from an unregulated compounding seller — a separate risk category no efficacy or safety study, topical or injectable, can speak to. For the full route-by-route breakdown, see our GHK-Cu side-effects review. None of this is a recommendation for or against GHK-Cu — talk to a licensed clinician about your own situation.